This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2021 Jul 27;326(4):352-353.

doi: 10.1001/jama.2021.3632.

Lipoprotein(a) and Cardiovascular Diseases

Hannah Miksenas¹, James L Januzzi Jr^{1

2}, Pradeep Natarajan^{1

2

3}

Affiliations

Affiliations

¹ Division of Cardiology, Massachusetts General Hospital, Boston.
² Department of Medicine, Harvard Medical School, Boston, Massachusetts.
³ Program in Medical and Population Genetics, Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, Massachusetts.

PMID: 34236417
DOI: 10.1001/jama.2021.3632

Lipoprotein(a) and Cardiovascular Diseases

Hannah Miksenas et al. JAMA. 2021.

. 2021 Jul 27;326(4):352-353.

doi: 10.1001/jama.2021.3632.

Authors

Hannah Miksenas¹, James L Januzzi Jr^{1

2}, Pradeep Natarajan^{1

2

3}

Affiliations

¹ Division of Cardiology, Massachusetts General Hospital, Boston.
² Department of Medicine, Harvard Medical School, Boston, Massachusetts.
³ Program in Medical and Population Genetics, Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, Massachusetts.

PMID: 34236417
DOI: 10.1001/jama.2021.3632

Erratum in

Error in Figure.
[No authors listed] [No authors listed] JAMA. 2022 Jan 4;327(1):86. doi: 10.1001/jama.2021.16187. JAMA. 2022. PMID: 34914822 Free PMC article. No abstract available.

No abstract available

PubMed Disclaimer

Comment in

The Role of Lipoprotein(a) in Cardiovascular Diseases.
Nachtigall M, Nachtigall RH. Nachtigall M, et al. JAMA. 2021 Nov 23;326(20):2078. doi: 10.1001/jama.2021.16747. JAMA. 2021. PMID: 34812871 No abstract available.

Similar articles

Lipoprotein(a): implications for clinical practice.
Block RC, Pearson TA. Block RC, et al. Curr Atheroscler Rep. 2005 Sep;7(5):327-9. doi: 10.1007/s11883-005-0041-1. Curr Atheroscler Rep. 2005. PMID: 16105473 Review. No abstract available.
[Clinical significance of and treatment options for increased lipoprotein(a)].
Zsíros N, Paragh G, Harangi M. Zsíros N, et al. Orv Hetil. 2014 Apr 20;155(16):607-14. doi: 10.1556/OH.2014.29877. Orv Hetil. 2014. PMID: 24733102 Review. Hungarian.
Lipoprotein(a) risk in women and efficacy of ascorbate.
Bostom AG. Bostom AG. JAMA. 1994 Oct 19;272(15):1169. JAMA. 1994. PMID: 7933344 No abstract available.
Lp(a)-lowering drugs bolster cardiovascular pipeline.
Dolgin E. Dolgin E. Nat Rev Drug Discov. 2020 Mar;19(3):154-155. doi: 10.1038/d41573-020-00028-w. Nat Rev Drug Discov. 2020. PMID: 32127677 No abstract available.
Editorial Lp(a) - the underestimated cardiovascular risk factor.
Mellwig KP. Mellwig KP. Clin Res Cardiol Suppl. 2017 Mar;12(Suppl 1):1. doi: 10.1007/s11789-017-0091-2. Clin Res Cardiol Suppl. 2017. PMID: 28236286 Free PMC article. No abstract available.

See all similar articles

Cited by

Myocardial Bridging-Induced Acute Coronary Syndrome: A Bridge Too Far.
Ramcharan P, Katwaroo AR, Hosein R, Maharaj N, Swarath SM, Seecheran V, Seecheran RV, Seecheran NA. Ramcharan P, et al. Cureus. 2024 Jun 10;16(6):e62052. doi: 10.7759/cureus.62052. eCollection 2024 Jun. Cureus. 2024. PMID: 38989362 Free PMC article.
Lipoprotein(a), Oxidized Phospholipids, and Progression to Symptomatic Heart Failure: The CASABLANCA Study.
Januzzi JL Jr, van Kimmenade RRJ, Liu Y, Hu X, Browne A, Plutzky J, Tsimikas S, Blankstein R, Natarajan P. Januzzi JL Jr, et al. J Am Heart Assoc. 2024 Jun 18;13(12):e034774. doi: 10.1161/JAHA.124.034774. Epub 2024 Jun 11. J Am Heart Assoc. 2024. PMID: 38860394 Free PMC article.
Associations between lipid abnormalities and diabetic retinopathy across a large United States national database.
Jeong H, Maatouk CM, Russell MW, Singh RP. Jeong H, et al. Eye (Lond). 2024 Jul;38(10):1870-1875. doi: 10.1038/s41433-024-03022-3. Epub 2024 Mar 23. Eye (Lond). 2024. PMID: 38521836
Delipid extracorporeal lipoprotein filter from plasma system: a new intensive lipid lowering therapy for patients with acute ischemic stroke.
Jiao Y, Yang Q, Ye T, Zhu J, Li Q, Han X, Dong Q. Jiao Y, et al. Front Neurol. 2024 Mar 6;15:1342751. doi: 10.3389/fneur.2024.1342751. eCollection 2024. Front Neurol. 2024. PMID: 38510381 Free PMC article.
Lipoprotein (a) as a Biomarker for Cardiovascular Diseases and Potential New Therapies to Mitigate Risk.
Mukherjee D, Nissen SE. Mukherjee D, et al. Curr Vasc Pharmacol. 2024;22(3):171-179. doi: 10.2174/0115701611267835231210054909. Curr Vasc Pharmacol. 2024. PMID: 38141196 Review.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems